GlassScriptPhysician profile
Michael Lawrence Foster
NPI 1588927719
$3,483.80
in general payments reported to CMS, 2019-2025
27 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $270 · 2021: $1,000 · 2022: $75.08 · 2023: $857 · 2024: $419 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,179 · Travel and Lodging: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.06 |
| Travel and Lodging | $314.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $466.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Intuitive Surgical, INC. | $380.35 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $215.27 | 2019-2024 | Airsupra, Andexxa, Breztri |
| Genzyme Corporation | $171.79 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.05 | 2019-2023 | Ofev, Stiolto Respimat |
| Abiomed | $146.57 | 2024 | Impella |
| Insmed, INC. | $100.46 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $92.20 | 2019-2020 | |
| Philips North America LLC | $85.51 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $70.97 | 2019-2024 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $68.07 | 2020-2024 | Opsumit |
| Electromed, INC. | $61.68 | 2022-2023 | Smartvest |
| Allergan, INC. | $54.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $52.51 | 2024-2025 | Zemaira |
| Takeda Pharmaceuticals U.S.A., INC. | $47.28 | 2023-2025 | Glassia |
| Mylan Specialty L.P. | $38.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.92 | 2020-2023 | Xarelto |
| Shire North American Group INC | $32.20 | 2019 | |
| Amgen INC. | $25.00 | 2023 | Tezspire |
| Jazz Pharmaceuticals INC. | $23.11 | 2019 | |
| Abbott Laboratories | $22.37 | 2025 | |
| Inogen, INC. | $20.03 | 2025 | |
| Boston Scientific Corporation | $19.19 | 2023 | Exalt Model D |
| Harmony Biosciences LLC | $17.34 | 2023 | Wakix |
| Medtronic, INC. | $15.45 | 2023 | Illumisite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.